×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: TREM2 Gene-Mechanism-Therapy Chain — From Genetic Risk to Th
mechanism
2,576 words
KG: ent-gene-28e2cb01
2026-03-28
kind:mechanism
section:mechanisms
state:published
evidence:strong
Contents
TREM2 Gene-Mechanism-Therapy Chain — From Genetic Risk to Therapeutic Target
🔬
Protein Info
Gene Symbol
ent-gene-28e2cb01
Function
primarily expressed on microglia in the central nervous system
KG Connections
5
knowledge graph edges
Databases
GeneCards
UniProt
NCBI Gene
HPA
STRING
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener
Score: 0.61
TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming
Score: 0.59
TREM2-SIRT1 Metabolic Senescence Circuit in Microglial Aging
Score: 0.59
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.59
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.58
Microglial-Mediated Tau Clearance Dysfunction via TREM2 Sign
Score: 0.53
TREM2-Mediated Microglial Dysfunction Disrupts Perivascular
Score: 0.53
Microglial TREM2 downregulation impairs damage-associated re
Score: 0.51
Disease-Associated Microglia Metabolic Reprogramming
Score: 0.50
TREM2-APOE4 Co-targeting — Simultaneous Correction of Lipid
Score: 0.49
Lactate/Pyruvate Ratio Dynamics in CSF as a Neuroinflammatio
Score: 0.49
Oligodendrocyte Remyelination Enhancement
Score: 0.47
Peripheral-Central Immune Decoupling Therapy
Score: 0.46
TREM2-Mediated Microglial Checkpoint Therapy
Score: 0.46
Stage-Selective TREM2 Agonism — Boosting DAM Phagocytosis in
Score: 0.46
Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in
Score: 0.46
TREM2 R47H Variant Correction — AAV-Mediated Rescue of Commo
Score: 0.45
TREM2-Dependent Microglial Surveillance Controls AQP4-Mediat
Score: 0.45
TREM2-Mediated Microglial Dysfunction Disrupts Oligodendrocy
Score: 0.45
Soluble TREM2 (sTREM2) as Therapeutic Mimic — Decoupling Pha
Score: 0.45
TREM2-DAP12 Signalosome Enhancement — Boosting PI3K-AKT-mTOR
Score: 0.45
TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinf
Score: 0.44
Astrocytic-Mediated Tau Clearance Dysfunction via TREM2 Sign
Score: 0.43
TREM2-P2RY12 Balance Restoration Therapy
Score: 0.37
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
APOE-TREM2 Interaction Modulation
Score: 0.48
Show 25 more
Related Analyses (30)
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · completed
Neuroinflammation and microglial priming in early Alzheimer'
neurodegeneration · archived
Neuroinflammation and microglial priming in early AD
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · archived
Mechanistic validation of SEA-AD differential expression hyp
neurodegeneration · failed
Do these mechanistic hypotheses explain layer-specific synap
neurodegeneration · failed
Do these mechanistic hypotheses from the SEA-AD Atlas bundle
neurodegeneration · failed
What are the optimal temporal windows for TREM2 inhibition v
neurodegeneration · failed
What are the optimal timing windows for TREM2 inhibition vs
neurodegeneration · failed
Does SYK activation provide neuroprotection or exacerbate ne
neurodegeneration · failed
Can TREM2 receptor switching from agonism to antagonism be a
neurodegeneration · failed
What are the optimal timing windows for TREM2 agonism vs ant
neurodegeneration · failed
Can biased TREM2 agonists selectively activate DAP12-SYK-PI3
molecular biology · failed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Show 25 more
Related Experiments (30)
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.40
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.40
TREM2 KO amyloid pathology study
validation · completed · Score: 0.75
TREM2 KO amyloid pathology study
validation · completed · Score: 0.75
TREM2 KO amyloid pathology study
validation · in_progress · Score: 0.75
TREM2 KO amyloid pathology study
validation · completed · Score: 0.75
TREM2 KO amyloid pathology study
validation · completed · Score: 0.75
TREM2 KO amyloid pathology study
validation · in_progress · Score: 0.75
TREM2 KO amyloid pathology study
validation · completed · Score: 0.75
s:** - GPR32 knockout in microglia should worsen neuroinflam
falsification · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
s:** - Compare tau strain spreading in EXT1/EXT2 conditional
falsification · proposed · Score: 0.40
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti
clinical · proposed · Score: 0.40
Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
validation · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Experiment: Autoimmune Hypothesis Testing in AD
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
validation · proposed · Score: 0.40
DLB Cognitive Fluctuation Mechanism Experiment
clinical · proposed · Score: 0.40
Genetic Risk Modifiers in DLB Phenotype
clinical · proposed · Score: 0.40
DLB Treatment Response Biomarkers — Predicting Cholinesteras
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40
Microglial Aging and Immune Memory in Neurodegeneration — Tr
validation · proposed · Score: 0.40
Microglial Contributions to Huntington's Disease Pathogenesi
validation · proposed · Score: 0.40
Mixed Pathology Effects on Parkinson's Disease Progression a
clinical · proposed · Score: 0.40
Non-Motor Symptom Progression in Parkinson's Disease — Mecha
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
trem2-therapeutics
therapeutic · Pages share 4 hypotheses
TREM2-Targeting Therapies
therapeutic · Pages share 4 hypotheses
TREM2 Modulator Therapy
therapeutic · Pages share 4 hypotheses
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
TREM2 Agonist Therapies for Alzheimer's Disease
therapeutic · Pages share 4 hypotheses
Neuroinflammation Modulation Therapy: GFAP and sTREM2-T
therapeutic · Pages share 4 hypotheses
TREM2 Signaling in Neurodegeneration
mechanism · Pages share 4 hypotheses
TREM2 in Parkinson's Disease — Cross-Disease Therapeuti
mechanism · Pages share 4 hypotheses
TREM2 Microglial Signaling Pathway in Neurodegeneration
mechanism · Pages share 4 hypotheses
TREM2 Microglia Pathway in Alzheimer's Disease
mechanism · Pages share 4 hypotheses
TREM2-APOE Axis in Neurodegeneration
mechanism · Pages share 4 hypotheses
TREM2 Therapeutics Investment Landscape
investment · Pages share 4 hypotheses
TREM2 Microglial Priming Inhibitor for Pre-Symptomatic
idea · Pages share 4 hypotheses
TREM1-TREM2 Balanced Microglial Modulation Therapy
idea · Pages share 4 hypotheses
sTREM2-Modulated Microglial Therapy
idea · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (5 edges)
ent-gene-28e2cb01
expressed_in
microglia
ent-gene-28e2cb01
data_in
ad_genetic_risk_loci:TREM2
ent-gene-28e2cb01
data_in
benchmark_ot_ad_answer_key:TREM2
ad_genetic_risk_loci:TREM2
data_in
ent-gene-28e2cb01
benchmark_ot_ad_answer_key:TREM2
data_in
ent-gene-28e2cb01